Efficacy and safety of N-acetyl-L-leucine in Niemann-Pick disease type C.
Tatiana Bremova-Ertl, Jens Claassen, Tomas Foltan...
https://pubmed.ncbi.nlm.nih.gov/34387740/Actively Recruiting
Led by IntraBio Inc · Updated on 2026-04-03
53
Participants Needed
14
Research Sites
24 weeks
Total Duration
Researchers are evaluating the safety, tolerability, and effectiveness of N-acetyl-L-leucine IB1001 compared to standard care for patients aged 4 years and older diagnosed with Niemann-Pick disease type C NPC. This is a pivotal, randomized, double-blind, placebo-controlled, multi-center study designed to provide important information on this treatments impact on NPC symptoms. The study includes a crossover design where participants receive both the study drug and placebo during separate periods. Participants will take N-acetyl-L-leucine or a placebo orally as granules suspended in water, orange juice, or almond milk. Patients aged 13 and older will receive a total daily dose of 4 grams divided into three doses, while those under 13 will receive weight-based dosing. The study consists of a baseline period followed by two treatment periods of about 12 weeks each, where participants switch from one treatment to the other. After completing the parent study, some patients may join an open-label extension phase providing up to three years of treatment. During the trial, participants will undergo assessments at several points, including before and after each treatment period. These include scales measuring ataxia severity, functional ability, disability, clinical global impressions from physicians, caregivers, and patients, and quality of life questionnaires. Researchers will monitor adherence and safety throughout the study. The trial continues until December 2030, with careful evaluation of the primary outcomes after each treatment phase and ongoing follow-up for those in the extension phase.
CONDITIONS
A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C
M
Michael Strupp, MD
T
Taylor Fields
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
IntraBio Inc
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | N-Acetyl-L-Leucine (IB1001) | Placebo |
|---|---|---|
| What it is | An oral investigational formulation of N-Acetyl-L-Leucine, a modified amino acid under evaluation for potential treatment effects in Niemann-Pick Disease Type C. | A matching oral placebo sachet designed to look and taste like the active investigational product but contains no N-Acetyl-L-Leucine. |
| Role in trial | Participants receive N-Acetyl-L-Leucine during one study period as the investigational therapy. | Participants receive placebo during the alternate study period to enable blinded comparison to the investigational treatment. |
| Primary use | Being studied to improve movement, ataxia, and functional abilities in Niemann-Pick Disease Type C. | Serves as a control to measure changes due to investigational treatment, without expected therapeutic effect. |
| How it is given or performed | Oral granules in a sachet, suspended in liquid, taken by mouth according to dosage schedule in the protocol. | Oral placebo granules in a matching sachet, taken by mouth in the same way and schedule as the active treatment. |
| Evidence status | Early-phase and multicenter studies suggest potential improvement in movement and neurologic symptoms, but larger confirmatory trials are ongoing and results are not yet established for this pivotal study. | No expected therapeutic benefit; acts as an inactive control to assess the effect of the investigational medicine. |
| Important limitations | Efficacy and safety have not been confirmed in large placebo-controlled studies as of this pivotal trial; previous studies had small samples and open-label designs, limiting the strength of existing evidence. | Provides no therapeutic benefit to participants and cannot address disease symptoms or progression, but is necessary for unbiased measurement of investigational effects. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 2 weeks
Participants undergo baseline assessments before starting treatment.
2 visits during the baseline period
Duration - Approximately 12 weeks
Participants receive either N-Acetyl-L-Leucine or placebo for approximately 12 weeks during the first intervention period.
2 visits during this treatment period
Duration - Approximately 12 weeks
Participants crossover to receive the opposite treatment (N-Acetyl-L-Leucine or placebo) for approximately 12 weeks during the second intervention period.
2 visits during this treatment period
Duration - Duration not specified
Participants who complete the main study may have the opportunity to continue receiving N-Acetyl-L-Leucine in an extension phase.
Visit schedule varies in the extension phase
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Tatiana Bremova-Ertl, Jens Claassen, Tomas Foltan...
https://pubmed.ncbi.nlm.nih.gov/34387740/Tatiana Bremova-Ertl, Uma Ramaswami, Marion Brands...
https://pubmed.ncbi.nlm.nih.gov/38294974/Mario Cortina-Borja, Danielle Te Vruchte, Eugen Mengel...
https://pubmed.ncbi.nlm.nih.gov/30115089/Niels Hendrickx, France Mentré, Alzahra Hamdan...
https://pubmed.ncbi.nlm.nih.gov/40739200/Ecem Kaya, David A Smith, Claire Smith...
https://pubmed.ncbi.nlm.nih.gov/33738443/Marc C Patterson, Uma Ramaswami, Aimee Donald...
https://pubmed.ncbi.nlm.nih.gov/40513057/IntraBio Inc
Lead Sponsor